▶ DSIP · SUBTOPIC · DOSING LITERATURE

DSIP Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of DSIP. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for DSIP reports the following route(s) of administration: Subcutaneous (research), Intranasal (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of DSIP.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for DSIP of approximately Very short (minutes) plasma · longer CNS retention reported. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of DSIP. Refer to the original publication for full protocol detail.

Schoenenberger GA, Monnier M (1977) reports the DSIP protocol used in The isolation of a peptide which induces delta-sleep, published in Pflugers Arch. PMID 195243. See the source for the protocol-level dose range, frequency, and duration. link
Graf MV, Kastin AJ (1986) reports the DSIP protocol used in Delta sleep-inducing peptide (DSIP): a review, published in Peptides. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What's the half-life of DSIP?

Very short plasma half-life (minutes). CNS retention is reportedly longer, but the molecule is rapidly cleared from circulation. This is why research protocols typically use subcutaneous administration shortly before the intended sleep onset.

▶ What is the research dose of DSIP?

Russian preclinical literature describes 25-100 mcg per administration, subcutaneous or intranasal, prior to sleep. No human dose is recommended by this wiki.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 14-28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ DSIP OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25